-
公开(公告)号:US20070021445A1
公开(公告)日:2007-01-25
申请号:US11488863
申请日:2006-07-18
申请人: Steven Berthel , Adrian Cheung , Kyungjin Kim , Shiming Li , Kshitij Thakkar , Weiya Yun
发明人: Steven Berthel , Adrian Cheung , Kyungjin Kim , Shiming Li , Kshitij Thakkar , Weiya Yun
IPC分类号: A61K31/519 , C07D487/04
CPC分类号: C07D471/04
摘要: The present invention comprises pyridopyrimidinediamine compounds of the general formula I: The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
摘要翻译: 本发明包括通式I的吡啶并嘧啶二胺化合物:本发明的化合物是PTP1B的有效抑制剂。 因此,本发明还包括治疗或预防PTP-1B介导的疾病(包括糖尿病,肥胖症和糖尿病相关疾病)的药物组合物和方法。
-
公开(公告)号:US20070270445A1
公开(公告)日:2007-11-22
申请号:US11823776
申请日:2007-06-27
申请人: Steven Berthel , Adrian Cheung , Kyungjin Kim , Kshitij Thakkar , Weiya Yun
发明人: Steven Berthel , Adrian Cheung , Kyungjin Kim , Kshitij Thakkar , Weiya Yun
IPC分类号: A61K31/519 , A61P3/00 , C07D487/04
CPC分类号: C07D487/04
摘要: The invention relates to pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds which are useful for inhibiting protein tyrosine phosphatases, particularly PTP1B, and are useful for lowering blood glucose concentrations in mammals.
-
公开(公告)号:US20060211715A1
公开(公告)日:2006-09-21
申请号:US11268300
申请日:2005-11-06
申请人: Steven Berthel , Adrian Cheung , Kshitij Thakkar , Weiya Yun
发明人: Steven Berthel , Adrian Cheung , Kshitij Thakkar , Weiya Yun
IPC分类号: A61K31/517 , C07D239/95
CPC分类号: C07D401/12 , C07D239/95 , C07D401/04 , C07D401/10 , C07D403/04 , C07D405/12 , C07D409/04 , C07D413/04
摘要: The present invention comprises aminoquinazoline compounds of the general formula I: wherein X is an unsubstituted or substituted phenyl, or is an unsubstituted or substituted 5 or 6 membered heteroaromatic ring. The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.
摘要翻译: 本发明包括通式I的氨基喹唑啉化合物:其中X是未取代或取代的苯基,或是未取代或取代的5或6元杂芳族环。 本发明的化合物是PTP1B的有效抑制剂。 因此,本发明还包括治疗或预防PTP-1B介导的疾病(包括糖尿病,肥胖症和糖尿病相关疾病)的药物组合物和方法。
-
公开(公告)号:US20070078165A1
公开(公告)日:2007-04-05
申请号:US11526523
申请日:2006-09-25
申请人: Steven Berthel , Shawn Erickson , Nader Fotouhi , Robert Kester , Kyungjin Kim , Steven Mischke , Yimin Qian , Kshitij Thakkar , Jefferson Tilley , Hong Wang
发明人: Steven Berthel , Shawn Erickson , Nader Fotouhi , Robert Kester , Kyungjin Kim , Steven Mischke , Yimin Qian , Kshitij Thakkar , Jefferson Tilley , Hong Wang
IPC分类号: A61K31/454 , C07D403/02
CPC分类号: C07D401/04 , C07D401/14 , C07D471/04
摘要: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of obesity, hyperphagia, anxiety, depression and related disorders and diseases.
摘要翻译: 本文提供式(I)的化合物及其药学上可接受的盐,其中取代基如说明书中公开的那些。 这些化合物和含有它们的药物组合物可用于治疗肥胖,食欲过盛,焦虑,抑郁和相关疾病和疾病。
-
公开(公告)号:US20100222325A1
公开(公告)日:2010-09-02
申请号:US12711312
申请日:2010-02-24
申请人: Steven Berthel , Fariborz Firooznia , Daniel Fishlock , Jun-Bae Hong , Yan Lou , Matthew Lucas , Timothy D. Owens , Keshab Sarma , Zachary Kevin Sweeney , Joshua Paul Gergely Taygerly
发明人: Steven Berthel , Fariborz Firooznia , Daniel Fishlock , Jun-Bae Hong , Yan Lou , Matthew Lucas , Timothy D. Owens , Keshab Sarma , Zachary Kevin Sweeney , Joshua Paul Gergely Taygerly
IPC分类号: A61K31/4725 , C07D413/14 , C07D401/14 , C07D401/10 , A61P29/00 , A61P37/00 , A61K31/5377 , A61K31/496 , A61K31/502
CPC分类号: C07D401/10 , C07D401/14 , C07D403/14 , C07D413/14
摘要: This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formulae I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.
摘要翻译: 本申请公开了根据通式I-III的5-苯基-1H-吡啶-2-酮,6-苯基-2H-哒嗪-3-酮和5-苯基-1H-吡嗪-2-酮衍生物:其中, 变量Q,R,X,X',Y1,Y2,Y2',Y3,Y4,Y5,m和n如本文所述限定Btk。 本文公开的化合物可用于调节Btk的活性并治疗与过量Btk活性相关的疾病。 该化合物还可用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病,例如类风湿性关节炎。 还公开了含有式I-III化合物和至少一种载体,稀释剂或赋形剂的组合物。
-
公开(公告)号:US08299077B2
公开(公告)日:2012-10-30
申请号:US12711312
申请日:2010-02-24
申请人: Steven Berthel , Fariborz Firooznia , Daniel Fishlock , Jun-Bae Hong , Yan Lou , Matthew Lucas , Timothy D. Owens , Keshab Sarma , Zachary Kevin Sweeney , Joshua Paul Gergely Taygerly
发明人: Steven Berthel , Fariborz Firooznia , Daniel Fishlock , Jun-Bae Hong , Yan Lou , Matthew Lucas , Timothy D. Owens , Keshab Sarma , Zachary Kevin Sweeney , Joshua Paul Gergely Taygerly
IPC分类号: A61K31/502 , C07D237/32
CPC分类号: C07D401/10 , C07D401/14 , C07D403/14 , C07D413/14
摘要: This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formula I-III: wherein, variables Q, R, X, X′, Y1, Y2, Y2′, Y3, Y4, Y5, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I-III and at least one carrier, diluent or excipient.
摘要翻译: 该申请公开了根据通式I-III的5-苯基-1H-吡啶-2-酮,6-苯基-2H-哒嗪-3-酮和5-苯基-1H-吡嗪-2-酮衍生物:其中, 变量Q,R,X,X',Y1,Y2,Y2',Y3,Y4,Y5,m和n如本文所述限定Btk。 本文公开的化合物可用于调节Btk的活性并治疗与过量Btk活性相关的疾病。 该化合物还可用于治疗与异常B细胞增殖相关的炎症和自身免疫疾病,例如类风湿性关节炎。 还公开了含有式I-III化合物和至少一种载体,稀释剂或赋形剂的组合物。
-
-
-
-
-